ENALAPRIL MALEATE (enalapril maleate) by Bristol Myers Squibb is 12. Approved for symptomatic heart failure, usually in combination with diuretics, digitalis and 2 more indications. First approved in 2021.
Drug data last refreshed 18h ago
12.1 Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also…
Worked on ENALAPRIL MALEATE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.